APC2
protein-codingAPC regulator of WNT signaling pathway 2, the group of Armadillo repeat containing
Gene summary
This gene encodes a strongly conserved protein that has an N-terminal coiled-coil domain followed by an armadillo domain, five 20-amino acid repeats, and two SAMP domains. This protein promotes the assembly of a multiprotein complex that recruits and phosphorylates the Wnt effector beta-catenin and targets beta-catenin for ubiquitylation and proteasomal degradation. This protein therefore plays a role in the reduction of cytoplasmic levels of beta-catenin which in turn reduces activation of Wnt target genes that play a pivotal role in the pathogenesis of various human cancers. The protein encoded by this gene is closely related to the adenomatous polyposis coli (APC) tumor-suppressor protein and has similar tumor-suppressor effects. This gene also plays a role in actin assembly, cell-cell adhesion, and microtubule network formation through its interaction with cytoskeletal proteins. This gene has its highest expression in the central nervous system and is involved in brain development through cytoskeletal regulation in neurons. Alternative splicing produces multiple transcript variants encoding distinct isoforms. [provided by RefSeq, May 2017]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~26.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0018838
Submitter: ClinGen
APC2 was first reported in relation to autosomal recessive lissencephaly spectrum disorders by Lee et al. in 2019 (PMID 31585108). Individuals with lissencephaly spectrum disorders related to APC2 pathogenic variants present with posterior predominant lissencephaly +/- corpus callosum dysgenesis, hypoplasia of the cerebellum, severe developmental delay , epilepsy with myoclonic or generalized tonic-clonic seizures. At least 9 unique variants predicted to cause loss of function have been reported in humans in association with autosomal recessive lissencephaly spectrum disorders . Evidence supporting this gene-disease relationship includes experimental data implicating APC2 plays a role in microtubule function at the axonal growth cone and Apc2 -/- mouse models demonstrating defects in the cortical lamina, as well as the cerebellum. Of note, this gene has also been implicated in Sotos Syndrome Type 3 which features intellectual disability and characteristic facial features. This association will be assessed separately in the future. Three years have elapsed since the first association between APC2 and lissencephaly spectrum disorders, so a definitive classification is warranted. This classification was approved by the ClinGen Brain Malformations gene curation expert panel on October 11, 2022 (SOP Version 9).
Inheritance Pattern: AR
Disease ID:MONDO:0032866
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0032866
Submitter: Ambry Genetics
Inheritance Pattern: Unknown
Disease ID:MONDO:0014951
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0032866
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0019349
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0032866
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to APC2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005883.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 355 | 18 | 375 | ||
| missense | 1 | 1 | 696 | 41 | 11 | 750 |
| nonsense | 3 | 1 | 2 | 6 | ||
| start loss | 0 | |||||
| frameshift | 9 | 11 | 3 | 23 | ||
| splice donor/acceptor (+/-2bp) | 3 | 1 | 4 | |||
| Total | 13 | 16 | 704 | 396 | 29 | 1158 |
Highest pathogenic variant AF is 0.0000058943933
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005874.1 | 14 | MANE Select | |
| Ensembl | ENSP00000467073.2 | 14 | MANE Select | |
| RefSeq | NP_001338202.1 | 14 | Standard | |
| Ensembl | ENSP00000233607.2 | 14 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Gastric cancer - Homo sapiens (human)
- Cushing,s syndrome - Homo sapiens (human)
- Breast cancer - Homo sapiens (human)
- HTLV-I infection - Homo sapiens (human)
- Regulation of actin cytoskeleton - Homo sapiens (human)
Biological Process
- microtubule cytoskeleton organization
- cell fate specification
- negative regulation of microtubule depolymerization
- pattern specification process
- Wnt signaling pathway
Molecular Function
- protein binding
- beta-catenin binding
- microtubule binding
- gamma-catenin binding
Cellular Component
- cytoplasm
- Golgi apparatus
- cytosol
- cytoplasmic microtubule
- actin filament
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000535453
- Coding exons
- 14
- Length
- 26944
- Individuals with no LoFs
- 125471
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 15
- Defined
- 125486
- p
- 0.0000598
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.754 | 1015 | 1.08e+3 | 0.936 | 0.0000664 | 14009 |
| Missense (PolyPhen) | 280 | 405.78 | 0.69003 | 5077 | ||
| Synonymous | -2.43 | 583 | 513 | 1.14 | 0.0000345 | 5159 |
| Loss of Function | 6.24 | 7 | 58.5 | 0.120 | 0.00000290 | 702 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000078 | 0.000062 | rare |
| Latino/Admixed American | 0.000064 | 0.000058 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00012 | 0.00011 | rare |
| Finnish | 0.00010 | 0.000092 | rare |
| European (Non-Finnish) | 0.000058 | 0.000053 | rare |
| South Asian | 0.000068 | 0.000065 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Stabilizes microtubules and may regulate actin fiber dynamics through the activation of Rho family GTPases (PubMed:25753423). May also function in Wnt signaling by promoting the rapid degradation of CTNNB1 (PubMed:10021369, PubMed:11691822, PubMed:9823329). {ECO:0000269|PubMed:10021369, ECO:0000269|PubMed:11691822, ECO:0000269|PubMed:25753423, ECO:0000269|PubMed:9823329}.;
- Disease
- DISEASE: Sotos syndrome 3 (SOTOS3) [MIM:617169]: A form of Sotos syndrome, a childhood overgrowth syndrome characterized by prenatal and postnatal overgrowth, developmental delay, mental retardation, advanced bone age, and abnormal craniofacial morphology. SOTOS3 patients do not have advanced bone age, hypotonia, seizures, or autism. SOTOS3 transmission pattern is consistent with autosomal recessive inheritance. {ECO:0000269|PubMed:25753423}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.142
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.991
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | High |
| Cancer | Medium | Medium | Medium |